PODD / Is Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes"

Shares of medical device company Insulet Corporation (NASDAQ: PODD) witnessed a remarkable surge, jumping by 14% on Friday in response to the company' more_horizontal

The automated insulin technology developer posts third-quarter revenue of $432.7 million, compared with $340.8 million a year earlier. more_horizontal

Insulet Corp. shares PODD, +1.98% climbed 10% premarket on Friday after the insulin pump maker late Thursday reported third-quarter results that beat more_horizontal

Insulet Corporation (NASDAQ:PODD ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Deborah Gordon - Vice President, more_horizontal

While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended September 2023, it could be more_horizontal

Today, we take a look at Insulet Corporation, a mid-cap medical device concern. The company is focused on developing and marketing insulin delivery sy more_horizontal

Insulet (PODD) is well positioned to outperform the market, as it exhibits above-average growth in financials. more_horizontal

The heavy selling pressure might have exhausted for Insulet (PODD) as it is technically in oversold territory now. In addition to this technical measu more_horizontal